Last reviewed · How we verify

Vimpat — Competitive Intelligence Brief

Vimpat (lacosamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

marketed Dihydropyrimidinase-related protein 2, Carbonic anhydrase 1, Carbonic anhydrase 12 Neuroscience Live · refreshed every 30 min

Target snapshot

Vimpat (lacosamide) — UCB.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Vimpat TARGET lacosamide UCB marketed Dihydropyrimidinase-related protein 2, Carbonic anhydrase 1, Carbonic anhydrase 12

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vimpat — Competitive Intelligence Brief. https://druglandscape.com/ci/lacosamide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: